In the global pharmaceutical world, few stories are as consequential right now as what is happening to weight-loss drugs in China. Semaglutide — the active ingredient in Novo Nordisk's blockbuster Ozempic and Wegovy — lost its patent protection in China on March 20, 2026. That date, years ahead of semaglutide's patent expiry in the United States (2032) or Europe, marks the opening of a new era: the era of GLP-1 generics in China.
The implications ripple far beyond pharmaceutical boardrooms. They touch on how hundreds of millions of Chinese people manage chronic illness, how the country's domestic drug industry rises to the global stage, and how Chinese society might reckon with an obesity epidemic that has been building quietly for decades.
The Obesity Crisis No One Was Talking About
To understand why GLP-1 generics matter so much in China, you first have to understand the scale of the health crisis they are entering.
China now has the largest absolute number of people living with overweight or obesity in the world. National surveys indicate that roughly half of all Chinese adults fall into one of these categories, as do about 20% of children and adolescents aged 6 to 17. Projections suggest that by 2030, approximately 65% of Chinese adults could be overweight or obese — up from just 25% in 2000. One epidemiological forecast puts the total obese population exceeding 500 million people by 2033.
The economic burden is staggering. Healthcare costs attributable to overweight and obesity in China already amounted to nearly 325 billion yuan in 2020, and analysts project those costs reaching 418 billion yuan annually by 2030 — roughly 21.5% of total national medical expenditures. Obesity drives up rates of type 2 diabetes, cardiovascular disease, hypertension, stroke, and certain cancers; China is already home to approximately 141 million people living with type 2 diabetes, the highest count anywhere on earth.
For a long time, this crisis was treated as a lifestyle issue — a matter of personal willpower and dietary choices. That framing is now beginning to shift. In 2024, China's National Health Commission and 16 government ministries jointly launched the "Year of Weight Management Initiative," calling for a scientific, medically-grounded understanding of weight. By April 2025, the NHC had issued formal guidelines for establishing weight management clinics, and the Healthy China initiative officially elevated weight management to a national strategic priority.
The cultural and policy ground is shifting — and into that shift, GLP-1 drugs are arriving.
What Are GLP-1 Drugs and Why Do They Matter?
GLP-1 receptor agonists work by mimicking a natural gut hormone that regulates blood sugar and appetite. Originally developed for type 2 diabetes, they were discovered to also produce meaningful and sustained weight loss — and then, remarkably, to confer additional benefits including cardiovascular risk reduction, protection against chronic kidney disease, and potential applications in metabolic fatty liver disease (MASH) and even neurodegenerative conditions like Alzheimer's.
Semaglutide (Ozempic for diabetes, Wegovy for obesity) became the defining drug of this class, generating roughly $14 billion in global diabetes sales and $4.5 billion in weight-loss sales in 2023 alone. Its rival tirzepatide from Eli Lilly — sold as Mounjaro for diabetes and Zepbound for obesity — has also proven highly effective, combining GLP-1 with GIP receptor agonism for what many clinicians consider superior weight-loss results.
In China, Ozempic was approved for type 2 diabetes in 2021 and quickly became Novo Nordisk's fastest-growing market — until it wasn't. In February 2026, Novo reported that Ozempic sales in China had declined 5% the previous year, the first such decline since the drug's Chinese approval. Novo's CEO acknowledged bluntly: "Pretty much all regions did well, with maybe the exception of China. We had higher hopes for China."
The reason is not hard to find.
The Generic Race: Fifteen Companies, One Patent Cliff
With semaglutide's Chinese patent expiry arriving years before the rest of the world, Chinese pharmaceutical companies launched a race that has few precedents in the industry's history. As of early 2026, at least 15 domestic companies are developing generic or biosimilar versions of semaglutide, with 11 candidates already in final-stage clinical trials. The leading companies include United Laboratories, CSPC Pharmaceutical Group, and Huadong Medicine — whose subsidiary Hangzhou Jiuyuan Gene Engineering was among the first to file for marketing approval of a semaglutide biosimilar with China's National Medical Products Administration (NMPA).
The wider pipeline is extraordinary in its depth. As of early 2025, China already had 60 to 70 late-stage pipeline assets competing with semaglutide and tirzepatide for diabetes and weight loss. About half target weight management specifically. Among these, eight are oral formulations — aiming to solve the inconvenience of weekly injections — and approximately 20 are dual-target or triple-target molecules designed to improve on semaglutide's efficacy. This is a pipeline arguably more competitive than anything seen in developed Western markets, where multinational companies have historically dominated the GLP-1 space.
One domestic asset deserving particular mention is mazdutide, developed by Innovent Biologics and backed by Eli Lilly, currently in phase 3 trials in China. Robust data from multiple cardiometabolic studies have generated significant clinical interest.
Why Manufacturing Complexity Is a Competitive Moat
Not every company that wants to make a GLP-1 generic can do so easily. These are biologics, not simple small-molecule drugs, and the manufacturing process — producing the active pharmaceutical ingredient and loading it correctly into injection pens — is technically demanding. Eli Lilly invested $24 billion since 2020 just in manufacturing infrastructure for its GLP-1 lineup. This complexity means that even after patent expiry, the number of viable competitors may be more limited than in typical small-molecule generic markets, and quality control will be a meaningful differentiator.
The Business Landscape: Price Wars, Procurement, and the Self-Pay Divide
When generics enter the market, pricing dynamics shift dramatically. Goldman Sachs analysts project price reductions of around 25% for semaglutide in China as competition intensifies. But the more dramatic mechanism is China's Volume-Based Procurement (VBP) system.
VBP, launched nationally in 2018, works by pooling hospital purchasing power to negotiate steep discounts from drug manufacturers in exchange for guaranteed sales volumes. It has historically produced price cuts of 50% to 90% in the categories it covers. When Novo Nordisk's long-acting and rapid-acting insulins were included in VBP, the company experienced substantial revenue impacts in what had been a billion-dollar segment in China. Semaglutide biosimilars, once multiple generics receive approval, are highly likely candidates for VBP inclusion — potentially compressing prices far more dramatically than Goldman's 25% estimate for the originator drug.
This creates an important strategic bifurcation. China's GLP-1 market currently operates on two distinct tracks:
Track 1: Reimbursed diabetes treatment. Ozempic is already listed on China's National Reimbursement Drug List (NRDL) for type 2 diabetes. In December 2025, Lilly's tirzepatide (Mounjaro) was added to the 2025 NRDL for the same indication, taking effect from January 1, 2026. For diabetes patients, these drugs are increasingly accessible through public insurance.
Track 2: Self-pay weight loss. Currently, no GLP-1 drug is reimbursed in China for obesity or weight management. Patients seeking GLP-1 therapies for weight loss pay entirely out of pocket — making the price-sensitivity of the Chinese consumer a central commercial question. The arrival of lower-cost generics could dramatically expand this self-pay market, particularly as obesity gains recognition as a medical condition rather than a personal failing.
For multinational companies like Novo Nordisk and Eli Lilly, this dual-track reality demands a fundamental rethink of strategy. Their brand equity, superior clinical data packages, and differentiated next-generation molecules (including oral formulations and longer-acting injectables) become their primary tools for defending market share against a wave of cheaper domestic alternatives.
China as a Pharma R&D Powerhouse
Something else is happening alongside the generic race that deserves attention: China is not just copying GLP-1 drugs. It is innovating with them.
The speed with which Chinese companies generate clinical data has become a competitive advantage recognized globally. Pharmaceutical M&A deals involving Chinese firms reached $92.2 billion in potential value through November 2025, nearly double the $51.9 billion recorded in 2024. Western pharma companies are actively seeking Chinese biotech assets — not just for their China market access, but for their novel molecules and clinical execution capabilities.
In the GLP-1 space specifically, China's domestic developers are not content to simply replicate semaglutide. They are working on dual and triple receptor agonists, oral formulations, and assets targeting emerging indications like MASH — a liver disease for which there remains no widely approved treatment globally. China's regulatory agency (NMPA) and the European Medicines Agency are reviewing semaglutide for MASH, while the FDA has approved only one treatment so far. Chinese developers see an early-mover opportunity here.
This trajectory matters for the global pharmaceutical order. China is transitioning from a "me-too" market into a source of genuine pharmaceutical innovation — and GLP-1 drugs are one of the clearest illustrations of that transition.
Societal Impact: What Affordable GLP-1s Could Mean for China
If generics successfully drive down prices and the government eventually moves toward reimbursement for obesity indications, the potential societal impact is enormous — though not without complexity.
Expanded Access to Metabolic Disease Treatment
The most direct impact is that more people with type 2 diabetes and obesity could access effective treatments. The current penetration of GLP-1 drugs in China remains low relative to the patient population that could clinically benefit. Cheaper generics — potentially administered through the VBP system to public hospitals — could change that calculus for millions.
A Shift in How Obesity Is Perceived
The government's own rhetoric has already shifted. Framing obesity as a disease requiring medical intervention — rather than a behavioral failure — is essential to unlocking reimbursement and clinical infrastructure. The arrival of effective, affordable GLP-1 medications could accelerate this cultural shift, just as the widespread availability of statins changed the way societies think about cholesterol management.
A Lancet review from late 2025 noted that five additional GLP-1 receptor agonists, including liraglutide, semaglutide, tirzepatide, and mazdutide, have been approved in China for weight management since 2021, "broadening therapeutic choices and initiating a transformation in obesity care." That transformation is only beginning.
The Urban-Rural Divide
There is a risk, however, that cheaper drugs alone do not solve access disparities. The GLP-1 market in China is predominantly concentrated in urban hospitals and driven by specialty endocrinology departments. Rural populations — who have seen disproportionate increases in obesity rates alongside urbanization — face barriers in healthcare infrastructure, physician awareness, and supply chain reach. VBP alone cannot bridge this divide; it will require deliberate policy investment in primary care capacity and obesity management infrastructure.
Long-term Healthcare Savings vs. Short-term Drug Spending
Policymakers face a genuine tension: GLP-1 drugs are expensive even at generic prices, and obesity requires long-term or lifelong treatment (studies show patients regain most lost weight within a year of stopping). Yet the downstream costs of untreated obesity — in diabetes complications, cardiovascular events, hospitalizations — are vastly higher. The economic case for reimbursement is strong in the long run; the political challenge is managing near-term insurance fund spending.
Global Ripple Effects
China's GLP-1 generic market will not stay contained within Chinese borders. As Chinese manufacturers scale up production and accumulate export ambitions, cheaper semaglutide versions will reach other emerging markets — India, Southeast Asia, Latin America — potentially at significant discounts to current global pricing. This could accelerate GLP-1 adoption in countries where cost has been the decisive barrier. It may also create regulatory and safety discussions in markets like the United States, where imports of cheaper foreign generics are illegal for personal use, but patient demand and awareness are rising.
What to Watch
The next 18 to 24 months will be defining ones for China's GLP-1 market. Several questions will shape the outcome:
Will the NMPA rapidly approve domestic semaglutide biosimilars? The speed of approvals will determine how quickly price competition intensifies and how many companies can viably compete.
Will VBP be extended to semaglutide biosimilars? If so, how aggressively will pricing be compressed, and will that actually translate into broader patient access or simply squeeze manufacturer margins without proportionally increasing uptake?
Will China reimburse GLP-1s for obesity? This is the single largest potential demand unlock. Political will, public health evidence, and insurance fund sustainability will all factor in.
Can domestic innovators take their molecules global? China's more advanced GLP-1 assets — particularly oral formulations and dual/triple receptor agonists — are already attracting interest from multinational partners. Whether they reach Western regulatory approval could signal a new phase of Chinese pharmaceutical influence.
How do multinationals respond? Novo Nordisk and Eli Lilly face a genuine strategic challenge. Their best tools are next-generation drugs (oral GLP-1s, monthly injectables), indication expansion into MASH and cardiovascular disease, brand equity, and doctor relationships. The China-specific pricing and go-to-market models they develop here may also inform their responses to patent cliffs in other emerging markets.
Conclusion
China's GLP-1 story is, at its core, about the collision of three forces: a public health crisis of obesity and metabolic disease that has been building for decades; a domestic pharmaceutical industry that has matured from copier to innovator; and a government increasingly willing to treat weight management as a medical — not merely behavioral — challenge.
The patent cliff on semaglutide in 2026 is the spark. The question is not whether China's GLP-1 market will transform, but how fast, how equitably, and with what consequences for the global pharmaceutical landscape.
For the hundreds of millions of Chinese people living with diabetes or obesity, the answer to that question is not merely commercial. It is about whether the most consequential medicines of the current era finally reach those who need them most.
Comments ()